TWI820037B - 醫療用材料、美容材料之製造方法及醫療用材料、美容材料 - Google Patents
醫療用材料、美容材料之製造方法及醫療用材料、美容材料 Download PDFInfo
- Publication number
- TWI820037B TWI820037B TW107129995A TW107129995A TWI820037B TW I820037 B TWI820037 B TW I820037B TW 107129995 A TW107129995 A TW 107129995A TW 107129995 A TW107129995 A TW 107129995A TW I820037 B TWI820037 B TW I820037B
- Authority
- TW
- Taiwan
- Prior art keywords
- water
- materials
- soluble
- medical
- cosmetic
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims abstract description 66
- 239000012567 medical material Substances 0.000 title claims abstract description 50
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 36
- 230000003796 beauty Effects 0.000 title description 8
- 150000004836 anionic polysaccharides Chemical class 0.000 claims abstract description 59
- 229920001586 anionic polysaccharide Polymers 0.000 claims abstract description 58
- 239000002537 cosmetic Substances 0.000 claims abstract description 56
- 150000003839 salts Chemical class 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 238000000465 moulding Methods 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 26
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 18
- 150000008065 acid anhydrides Chemical class 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 description 32
- 229940010747 sodium hyaluronate Drugs 0.000 description 32
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 13
- 239000002585 base Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- -1 acetyl heparin sulfate Chemical compound 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- BTOVVHWKPVSLBI-UHFFFAOYSA-N 2-methylprop-1-enylbenzene Chemical compound CC(C)=CC1=CC=CC=C1 BTOVVHWKPVSLBI-UHFFFAOYSA-N 0.000 description 2
- 229920000045 Dermatan sulfate Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 229920002522 Wood fibre Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002025 wood fiber Substances 0.000 description 1
- 230000037330 wrinkle prevention Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
- C08L1/08—Cellulose derivatives
- C08L1/26—Cellulose ethers
- C08L1/28—Alkyl ethers
- C08L1/286—Alkyl ethers substituted with acid radicals, e.g. carboxymethyl cellulose [CMC]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
- C08L1/08—Cellulose derivatives
- C08L1/26—Cellulose ethers
- C08L1/28—Alkyl ethers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/04—Alginic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本發明係提供:對皮膚等的密接性與服貼感均優異,且能徐緩釋出機能性成分連續式供應給操作部等處的醫療用/美容片之簡便製造方法,以及利用該製造方法進行製造的醫療用/美容片。本發明的醫療用材料、美容材料之製造方法,係包括有:將含有黏度平均分子量10,000以下的第1多價陰離子性多醣類之水溶性鹽、及黏度平均分子量50,000以上的第2多價陰離子性多醣類之水溶性鹽的原材料,施行成形而獲得水溶性成形體的步驟。又,本發明的醫療用材料、美容材料係利用該製造方法進行製造。
Description
本發明係關於醫療用材料、美容材料之製造方法、及醫療用材料、美容材料。
已知例如玻尿酸、海藻酸等多價陰離子性多醣類,呈現適度的黏性、黏著性、保濕性、及生物相容性。所以,該等多價陰離子性多醣類及其鹽便被廣泛使用為例如醫療用材料、食品用材料及化妝品用材料等的原材料。其中,因為玻尿酸具有保水性等優異特徵物性,且安全性與生物相容性高,而利用於例如:食品、化妝品、及醫藥品等各種用途。
再者,目的在於對肌膚賦予濕潤、防止皺紋等之美容片(化妝片)受到注目。例如有提案在源自木材纖維的紙上黏貼保濕劑等之皺紋改善片(專利文獻1)。又,有提案:使由玻尿酸製奈米纖維所形成的網孔狀構造體上,載持著保濕劑的化妝用片材(專利文獻2)。又,有提案:使由玻尿酸等水溶性多醣類所構成基材,含有保濕成分的電場紡絲片(專利文獻3)。
[專利文獻1]日本專利第3215852號公報
[專利文獻2]日本專利特開2008-179629號公報
[專利文獻3]國際公開第2009/036120號
然而,專利文獻1所提案的皺紋改善片,因為基材係紙,而容易破裂,且對皮膚的密接性、服貼感不足。又,專利文獻2與3所提案的片材,因為必需利用電紡絲法、電場紡絲法等方法進行製造,而製造步驟繁雜。又,與專利文獻1所提案的皺紋防止片材同樣,對皮膚的密接性、服貼感嫌不足。
另外,玻尿酸等多價陰離子性多醣類及其鹽等機能性成分,最好徐緩釋出連續式供應給操作部、患部。然而,專利文獻1~3所提案的片材,針對機能性成分的漸放性並無任何檢討。
本發明係有鑑於此種習知技術的問題而完成,課題在於提供:對皮膚等的密接性與服貼感均優異,且能徐緩釋出機能性成分連續式供應給操作部等處的醫療用/美容片之簡便製造方法。又,本發明課題在於提供:對皮膚等的密接性與服貼感均優異,且能徐緩釋出機能性成分連續式供應給操作部等處的醫療用/美容片。
即,根據本發明所提供的醫療用材料、美容材料之製造方法(以下亦稱「第1製造方法」),係包括有:將含有黏度平均分子量10,000以下的第1多價陰離子性多醣類之水溶性鹽、及黏度平均分子量50,000以上的第2多價陰離子性多醣類之水溶性鹽的原材料,施行成形而獲得水溶性成形體的步驟。
再者,根據本發明所提供的醫療用材料、美容材料之製造方法(以下亦稱「第2製造方法」),係包括有:含有將黏度平均分子量10,000以下的第1多價陰離子性多醣類之水溶性鹽、及黏度平均分子量50,000以上的第2多價陰離子性多醣類之水溶性鹽的原材料,施行成形而獲得水溶性成形體的步驟;以及對所獲得上述水溶性成形體施行水不溶化處理的步驟。
再者,根據本發明所提供的醫療用材料、美容材料(以下亦稱「第1醫療用材料、美容材料」),係利用上述第1製造方法進行製造。
再者,根據本發明所提供的醫療用材料、美容材料(以下亦稱「第2醫療用材料、美容材料」),係利用上述第2製造方法進行製造。
根據本發明可提供:對皮膚等的密接性與服貼感均優異,且能 徐緩釋出機能性成分連續式供應給操作部等處的醫療用/美容片之簡便製造方法。又,根據本發明可提供:對皮膚等的密接性與服貼感均優異,且能徐緩釋出機能性成分連續式供應給操作部等處的醫療用/美容片。
5‧‧‧孔
10‧‧‧托盤
圖1係黏度平均分子量1,500,000(150萬Da)及10,000(1萬Da)的玻尿酸鈉,經分析所獲得的色層分析圖。
圖2係從實施例1所製造膜中溶出的玻尿酸鈉濃度經時變化圖。
圖3係從實施例3所製造膜中溶出的玻尿酸鈉濃度經時變化圖。
圖4係從實施例2所製造膜中溶出的玻尿酸鈉濃度經時變化圖。
圖5係從實施例4所製造膜中溶出的玻尿酸鈉濃度經時變化圖。
圖6係實施例5所使用托盤的形狀說明示意圖。
以下,針對本發明實施形態進行說明,惟本發明並不僅侷限於以下實施形態。
<醫療用材料、美容材料及其製造方法>
本發明醫療用材料、美容材料之製造方法(第1製造方法),係 包括有:將含有黏度平均分子量10,000以下的第1多價陰離子性多醣類之水溶性鹽、及黏度平均分子量50,000以上的第2多價陰離子性多醣類之水溶性鹽的原材料,施行成形而獲得水溶性成形體的步驟。又,本發明第1醫療用材料、美容材料係利用上述第1製造方法進行製造。又,本發明醫療用材料、美容材料之製造方法(第2製造方法),係包括有:將含有黏度平均分子量10,000以下的第1多價陰離子性多醣類之水溶性鹽、及黏度平均分子量50,000以上的第2多價陰離子性多醣類之水溶性鹽的原材料,施行成形而獲得水溶性成形體的步驟;以及將所獲得水溶性成形體施行水不溶化處理的步驟。而,本發明第2醫療用材料、美容材料係利用上述第2製造方法進行製造。以下,針對本發明醫療用材料、美容材料及其製造方法的詳細內容進行說明。
水溶性成形體係使用含有多價陰離子性多醣類的水溶性鹽之原材料形成。多價陰離子性多醣類係分子構造中具有羧基、磺酸基等帶負電荷之1以上陰離子性基的多醣類。又,多價陰離子性多醣類的水溶性鹽係多價陰離子性多醣類中的陰離子性基至少其中一部分形成鹽。另外,多價陰離子性多醣類中的陰離子性基亦可導入於多醣類的分子中。
多價陰離子性多醣類的具體例係可舉例如:羧甲基纖維素、羧乙基纖維素等羧烷基纖維素;羧甲基澱粉、羧甲基直鏈澱粉、硫酸軟骨膠(包括有:軟骨膠-4-硫酸與軟骨膠-6-硫酸)、玻尿酸、肝素、肝素硫酸、硫酸乙醯肝素(heparan sulfate)、海藻酸、果膠、鹿角菜 膠、皮膚素硫酸、及皮膚素-6-硫酸等。該等多價陰離子性多醣類係可單獨使用一種、或組合使用二種以上。
多價陰離子性多醣類的水溶性鹽係可例如:無機鹽、銨鹽、及有機胺鹽等。無機鹽的具體例係可舉例如:鈉、鉀等鹼金屬鹽;鈣鹽等鹼土族金屬鹽;鋅、鐵等金屬鹽等等。
第1多價陰離子性多醣類的水溶性鹽之黏度平均分子量係10,000以下、較佳係1,000~5,000。又,第2多價陰離子性多醣類的水溶性鹽之黏度平均分子量係50,000以上、較佳係100,000~2,000,000。依此,藉由組合使用不同黏度平均分子量的二種多價陰離子性多醣類之水溶性鹽,便可獲得對皮膚等的密接性與服貼感均優異,且能徐緩釋出機能性成分連續式供應給操作部等處的本發明醫療用/美容片。
黏度平均分子量係可利用公知測定方法進行求取。具體而言,將多價陰離子性多醣類或其鹽(乾燥物)溶解於0.2M氯化鈉溶液中,利用烏伯羅德式黏度計求取30±0℃的極限黏度(η),根據Laurent公式(η(極限黏度)=3.6×10-4‧M0.78(M:黏度平均分子量))計算出黏度平均分子量。極限黏度(η)係根據第16修訂日本藥典一般試驗法黏度測定法 第1法:毛細管黏度計法進行測定。
第1製造方法的情況,更具體而言,利用黏度平均分子量相對較大的高分子量之第2多價陰離子性多醣類之水溶性鹽,形成對皮 膚等的密接性與服貼感優異之基材。然後,使所形成的基材載持著黏度平均分子量相對小的低分子量之第1多價陰離子性多醣類之水溶性鹽。所以,第1多價陰離子性多醣類的水溶性鹽會被徐緩從基材中釋出,可認為能持續性供應給操作部等。
再者,第2製造方法的情況,更具體而言,藉由將由黏度平均分子量相對大的高分子量之第2多價陰離子性多醣類之水溶性鹽所形成基材,施行水不溶化處理,便形成對皮膚等的密接性與服貼感優異的水不溶性基材。另一方面,更低分子量之第1多價陰離子性多醣類的水溶性鹽,因為黏度平均分子量相對小,而即便施行水不溶化處理,但仍幾乎不會構成基材,形成由高分子量之第2多價陰離子性多醣類所形成之基材載持的狀態。所以,判斷低分子量多價陰離子性多醣類會被徐緩從基材釋出,並持續性供應給操作部等。
在供獲得水溶性成形體(第1醫療用材料、美容材料)用的原材料中,所含第1多價陰離子性多醣類的水溶性鹽量,相對於第2多價陰離子性多醣類的水溶性鹽100質量份,較佳係1~150質量份、更佳係10~100質量份。第1多價陰離子性多醣類的水溶性鹽量,相對於第2多價陰離子性多醣類的水溶性鹽100質量份若未滿1質量份,則釋出的機能性成分量變少,會有成為醫療用/美容片時的效果不足之情況。另一方面,第1多價陰離子性多醣類的水溶性鹽量,相對於第2多價陰離子性多醣類的水溶性鹽100質量份若超過150質量份,則因為載持機能性成分的基材量變少,而操作性與強度會略降低。
屬於水溶性成形體的第1醫療用材料、美容材料,係例如將由多價陰離子性多醣類的水溶性鹽溶解於水中,而獲得的原材料(水溶液)成形為所需形狀後,經乾燥等便可獲得。水溶性成形體的形狀係可例如:片狀、薄膜狀、海綿狀、粉末狀、繩狀等。藉由將該等形狀之水溶性成形體施行水不溶化處理,便可獲得例如片狀、薄膜狀、海綿狀、粉末狀、繩狀等配合用途形狀的第2醫療用材料、美容材料。另外,視需要亦可將所獲得醫療用材料、美容材料更進一步施行成形加工成為所需形狀。
例如將原材料(水溶液)流入適當容器後,經乾燥或冷凍乾燥,便可獲得片狀、薄膜狀或海綿狀的水溶性成形體。藉由將原材料(水溶液)從噴嘴中擠出於不良溶劑中,便可獲得纖維狀水溶性成形體。將原材料(水溶液)填充於適當的管中之後,經乾燥或冷凍乾燥,便可獲得繩狀原料成形體。依此根據本發明的製造方法,便可獲得配合用途形狀的醫療用材料、美容材料。
第2製造方法中,將水溶性成形體施行水不溶化處理的手法並無特別的限定,可採用習知公知手法。將水溶性成形體施行水不溶化處理的手法具體例,係可舉例如:使用交聯劑進行化學性交聯而施行水不溶化的方法;照射電子束使其進行交聯而施行水不溶化的方法;使用多價金屬離子,利用離子鍵進行交聯而施行水不溶化的方法;使接觸於含酸酐處理液而施行水不溶化的方法等。其中,使原料成形體接觸於含酸酐處理液的方法係較為簡便,且能充分且迅 速地將水溶性成形體施行水不溶化處理,故較佳。另外,當將使用多價陰離子性多醣類之水溶性鹽形成的水溶性成形體,利用含醋酸酐等酸酐的處理液施行處理時,關於推測之反應機構等係例如國際公開第2015/029892號、日本專利特開2016-163695號公報等所揭示。
處理液所使用酸酐的具體例,係可舉例如:醋酸酐、丙酸酐、琥珀酸酐、丁酸酐、酞酸酐、及順丁烯二酸酐等。其中,較佳係醋酸酐與丙酸酐。該等酸酐係可單獨使用一種、或組合使用二種以上。
處理液較佳係更進一步含有水及水溶性有機溶劑中之至少任一介質,且在該介質中溶解或分散酸酐。藉由使用在此種介質中溶解或分散酸酐的處理液,便可使水溶性成形體充分且迅速地水不溶化。
水溶性有機溶劑的具體例,係可舉例如:甲醇、乙醇、丙醇、二甲基亞碸(DMSO)、乙腈、及四氫呋喃等。其中,較佳係甲醇、乙醇及二甲基亞碸。該等水溶性有機溶劑係可單獨使用一種、或組合使用二種以上。
處理液中的酸酐濃度通常係0.1~50質量%、較佳係5~30質量%。若酸酐濃度未滿0.1質量%,則所獲得第2醫療用材料、美容材料會有水不溶化程度不足、或者水不溶化需要長時間的傾向。另一方面,若酸酐濃度超過50質量%,則會有效果已達極限的傾向。
另外,因為多價陰離子性多醣類的親水性高,而就從使水溶性成形體更充分且迅速水不溶化的觀點,較佳係處理液的介質係含有水。處理液中的水含量,較佳係設為水溶性成形體不會溶解或膨潤的程度。具體而言,處理液中的水含量較佳係0.01~50質量%、更佳係5~20質量%。若處理液中的水含量未滿0.01質量%,則甲醇以外的溶劑會有出現水不溶化不足的情況。又,若處理液中的水含量超過50質量%,則會有所獲得醫療用材料、美容材料的形狀維持困難之情況。
水不溶化步驟中,最好使水溶性成形體接觸於含酸酐處理液,而施行水溶性成形體的水不溶化。藉由使水溶性成形體接觸於處理液,便可在維持形狀情況下,將水溶性成形體施行水不溶化,俾能獲得對應形狀的醫療用材料、美容材料。使水溶性成形體接觸於處理液的方法並無特別的限定,最好使處理液接觸到水溶性成形體全體,依處理液滲透至水溶性成形體內部的方式施行處理。具體的處理方法係可例如:將水溶性成形體浸漬於處理液中、或朝水溶性成形體塗佈或吹抵(噴霧)處理液等方法。
水不溶化處理時的溫度係在不超過處理液沸點溫度之前提下,其餘並無特別的限定。就從抑制多價陰離子性多醣類的分解改質觀點、以及抑制介質、副產物等揮散的觀點,處理時的溫度較佳係0~80℃、更佳係0~70℃、特佳係室溫(25℃)~60℃。但,若在處理時處理液不會揮散之條件下,利用例如熱衝壓、熱輥等施行處 理,便不會生成分解改質等,可依更短時間施行處理。例如利用熱衝壓、熱輥等施行處理時,處理時的溫度較佳係50~90℃,處理時間較佳係30分鐘以下。第2製造方法時,經水不溶化處理後,視需要使用水、水溶性有機溶劑等施行洗淨等,便可獲得第2醫療用材料、美容材料。
若使接觸於含酸酐處理液,而對水溶性成形體施行水不溶化處理,即在未使用交聯劑情況下,對水不溶性成形體施行水不溶化處理,則構成所獲得醫療用材料、美容材料的分子中,不會吸收源自交聯劑的官能基等構造。而使接觸於含酸酐處理液,對水溶性成形體施行水不溶化處理而獲得的第2醫療用材料、美容材料,可載持屬於原料的多價陰離子性多醣類之原本特性,且安全性更高,而更適用為醫療用材料、美容材料。另外,醫療用材料、美容材料的厚度並無特別的限定,較佳係20~200μm、更佳係60~120μm。
本說明書中所謂「水不溶性」係指不容易溶解於水中的性質。更具體而言,本發明第2醫療用材料、美容材料係利用水形成膨潤狀態後再施行乾燥,重複施行此項操作計2次,所獲得乾燥體的質量達該操作前乾燥質量的80%以上。
本發明第2醫療用材料、美容材料的膨潤率較佳係6,000質量%以下、更佳係900質量%以下、特佳係100~500質量%、最佳係150~350質量%。本說明書中所謂「膨潤率」係指「水分載持後(膨潤後)的第2醫療用材料、美容材料質量」,相對於「水分載持前(膨 潤前)的第2醫療用材料、美容材料質量」之比例(質量%)。另外,藉由將水不溶化步驟時所使用處理液中的水量,在例如不超過20質量%範圍內增加,便可製造膨潤率較低(例如6,000質量%以下)的第2醫療用材料、美容材料。又,藉由增加處理液中的酸酐量(例如上限20質量%),便可製造膨潤率較低(例如6,000質量%以下)的第2醫療用材料、美容材料。
使水溶性成形體接觸於含酸酐處理液,而使水溶性成形體呈水不溶化時,構成所獲得第2醫療用材料、美容材料的多價陰離子性多醣類分子,實質並沒有交聯。又,在多價陰離子性多醣類中實質沒有形成新的共價鍵。但,推測在多價陰離子性多醣類的分子間有形成例如:氫鍵、疏水鍵、及凡得瓦耳力等物理性鍵結。關於此種在多價陰離子性多醣類分子間有形成物理性鍵結的情形,利用紅外吸收光譜測定便可確認。
本發明第2醫療用材料、美容材料係在從酸性至鹼性的廣範圍pH域中呈穩定的水不溶性者。但,若例如接觸或浸漬於pH12以上水性介質等情況,分子間彼此間的物理性鍵結會解離而容易溶解。又,相較於第2多價陰離子性多醣類的水溶性鹽,第1多價陰離子性多醣類的水溶性鹽較不易被水不溶化。而,本發明第2醫療用材料、美容材料,較輕易從由經水不溶化第2多價陰離子性多醣類所構成基材,溶出第1多價陰離子性多醣類的水溶性鹽。
以下,針對本發明根據實施例進行具體說明,惟,本發明並不僅侷限於該等實施例。另外,實施例、比較例中的「份」及「%」在無特別聲明前提下,係質量基準。
<醫療用材料、美容材料之製造(1)>
(實施例1)
將玻尿酸鈉(黏度平均分子量150萬Da、Kikkoman Biochemifa公司製)粉末1g、玻尿酸鈉(黏度平均分子量1萬Da、Kikkoman Biochemifa公司製)粉末1g、甘油(日本藥典)0.5g、及水97.5g予以混合,調製得水溶液100g。將所調製水溶液100g流入於長12cm×寬10cm不鏽鋼托盤中,於20℃恆溫槽內進行乾燥,獲得含有甘油且厚度約50μm的膜(水溶性膜)。
(實施例2)
將實施例1所製造的水溶性膜浸漬於處理液(醋酸酐:乙醇=20:80)中,在50℃下放置1小時而施行水不溶化處理,獲得厚度約55μm的膜。
(實施例3)
將玻尿酸鈉(黏度平均分子量150萬Da、Kikkoman Biochemifa公司製)粉末1g、玻尿酸鈉(黏度平均分子量1萬Da、Kikkoman Biochemifa公司製)粉末1g、及水98g予以混合,調製得水溶液100g。將所調製水溶液流入於不鏽鋼製大桶中,依-30℃冷凍後,再利用棚架加熱溫度120℃施行冷凍乾燥,獲得海綿狀成形體(水溶性成形 體)。
(實施例4)
將實施例3所製造的水溶性成形體浸漬於處理液(醋酸酐:甲醇=10:90)中,於室溫下放置18小時而施行水不溶化處理。接著,依序利用甲醇、80體積%甲醇水溶液、及水施行洗淨,獲得海綿狀成形體。
<評價>
(玻尿酸鈉濃度測定)
使用以下所示構成的HPLC系統,測定由測定對象物利用0.3%NaOH水溶液溶解,而調製得試料(10μL)中的玻尿酸鈉濃度。分析黏度平均分子量1,500,000(150萬Da)及10,000(1萬Da)玻尿酸鈉,所獲得色層分析圖係如圖1所示。
泵:商品名「PU-980」(日本分光公司製)
自動取樣器:商品名「AS-950-10」(日本分光公司製)
管柱烘箱:商品名「CO-965」(日本分光公司製)
UV檢測器:商品名「UV-970」(日本分光公司製)
GPC管柱:商品名「TSKgel PWXL」(直徑4.6mm×300mm×2支、東曹公司製)
移動相:0.1N NaCl水溶液
流速:1.0mL/min
管柱溫度:40℃
(溶解試驗(1))
將實施例1與3所製造的膜切斷而製作2cm×2cm試驗片。在直徑3.5cm、深1.5cm容器中放入所製作的試驗片,添加PBS緩衝液(pH6.8)5mL。該容器放入調整為37℃的恆溫槽中靜置。經時性抽出緩衝液,測定玻尿酸鈉濃度。緩衝液的玻尿酸鈉濃度測定結果係如圖2與3所示。如圖2與3所示,實施例1與3所製造的膜係在低分子量玻尿酸鈉迅速溶出後,便徐緩溶出高分子量玻尿酸鈉。藉此得知可提供迅速釋出對皮膚滲透性高的低分子量玻尿酸鈉,同時徐緩溶解高分子量玻尿酸鈉,成為皮膜狀能保護皮膚表面等的醫療用/美容片。
(溶解試驗(2))
將實施例2與4所製造的膜切斷而製作2cm×2cm試驗片。在直徑3.5cm、深1.5cm容器中放入所製作的試驗片,添加PBS緩衝液(pH6.8)5mL。該容器放入調整為37℃的恆溫槽中,使用振盪機,依10~20rpm振盪24小時。經時性抽出緩衝液,測定玻尿酸鈉濃度。緩衝液的玻尿酸鈉濃度測定結果係如圖4與5所示。如圖4與5所示,實施例2與4所製造的膜雖有檢測到低分子量玻尿酸鈉溶出,但並未檢測到高分子量玻尿酸鈉溶出。藉此得知可提供迅速釋出低分子量玻尿酸鈉並持續性供應給操作部等,且可利用高分子量玻尿酸鈉保護皮膚與器官表面的醫療用/美容片。
<醫療用材料、美容材料之製造(2)>
(實施例5)
將玻尿酸鈉(黏度平均分子量150萬Da、Kikkoman Biochemifa公司製)粉末1g、玻尿酸鈉(黏度平均分子量0.5萬Da、Kikkoman Biochemifa公司製)粉末0.5g、及水98.5g予以混合,而調製得水溶液100g。準備如圖6所示,邊長1.5cm、深1cm、且具備有20個孔5的聚對苯二甲酸乙二酯製托盤10。在該托盤10的孔5中,每次流入所調製水溶液1mL後,放置於-80℃冷凍庫內進行冷凍。所獲得冷凍物施行真空冷凍乾燥(真空度-20Pa、棚架溫度25℃),獲得海綿狀固態物計20片。將1片所獲得海綿狀固態物放置於手背上,利用化妝水展開。藉此得知對皮膚供應低分子量玻尿酸鈉,且能獲得由高分子量玻尿酸鈉造成的皮膚保護與保濕效果。
(實施例6)
除取代玻尿酸鈉(黏度平均分子量150萬Da),改為使用海藻酸鈉(黏度平均分子量40萬Da、和光純藥公司製)之外,其餘均依照與前述實施例5同樣,獲得由高分子量海藻酸鈉-低分子量玻尿酸鈉構成的海綿狀固態物。
(實施例7)
除取代玻尿酸鈉(黏度平均分子量150萬Da),改為使用羧甲基纖維素鈉(黏度平均分子量15萬Da、東京化成公司製)之外,其餘均依照與前述實施例5同樣,獲得由高分子量羧甲基纖維素鈉-低分子量玻尿酸鈉構成的海綿狀固態物。
(產業上之可利用性)
本發明的醫療用材料、美容材料,係可效率佳地輕易溶出容易滲透肌膚的低分子量多價陰離子性多醣類(或其鹽),且可將保護效果高的高分子量多價陰離子性多醣類(或其鹽)長時間維持於操作部,而能有效使用為醫療用材料、美容材料。
Claims (5)
- 一種醫療用材料、美容材料之製造方法,係包括有:將含有黏度平均分子量1,000以上且10,000以下的第1多價陰離子性多醣類之水溶性鹽、及黏度平均分子量100,000以上且2,000,000以下的第2多價陰離子性多醣類之水溶性鹽的原材料,施行成形而獲得水溶性成形體的步驟;以及使所獲得上述水溶性成形體與含酸酐處理液接觸,維持上述水溶性成形體之形狀下施行水不溶化處理,形成第2多價陰離子性多醣類之水溶性鹽經水不溶化的水不溶性之基材、以及由上述基材所載持之第1多價陰離子性多醣類之水溶性鹽的步驟。
- 如請求項1之醫療用材料、美容材料之製造方法,其中,上述酸酐係醋酸酐及丙酸酐中至少任一者。
- 如請求項1或2之醫療用材料、美容材料之製造方法,其中,上述水溶性成形體的形狀係片狀、薄膜狀、海綿狀、粉末狀、或繩狀。
- 如請求項1或2之醫療用材料、美容材料之製造方法,其中,上述多價陰離子性多醣類係從玻尿酸、羧甲基纖維素、及海藻酸所構成群組中選擇至少一種。
- 一種醫療用材料、美容材料,係利用請求項1至4中任一項之製造方法進行製造。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017169099A JP6912327B2 (ja) | 2017-09-04 | 2017-09-04 | 医療用・美容材料の製造方法及び医療用・美容材料 |
JP2017-169099 | 2017-09-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201919575A TW201919575A (zh) | 2019-06-01 |
TWI820037B true TWI820037B (zh) | 2023-11-01 |
Family
ID=65525244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107129995A TWI820037B (zh) | 2017-09-04 | 2018-08-28 | 醫療用材料、美容材料之製造方法及醫療用材料、美容材料 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11491097B2 (zh) |
EP (1) | EP3680255A4 (zh) |
JP (1) | JP6912327B2 (zh) |
KR (1) | KR102322976B1 (zh) |
CN (1) | CN111051351A (zh) |
AU (1) | AU2018326846B2 (zh) |
CA (1) | CA3074674C (zh) |
SG (1) | SG11202001216WA (zh) |
TW (1) | TWI820037B (zh) |
WO (1) | WO2019044519A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101887980B1 (ko) | 2016-11-09 | 2018-08-13 | 현대오트론 주식회사 | Dct 차량의 변속제어방법 |
JP7104942B2 (ja) * | 2020-08-28 | 2022-07-22 | 日本コルマー株式会社 | ゲル状組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007297460A (ja) * | 2006-04-28 | 2007-11-15 | Q P Corp | 新規なヒアルロン酸および/またはその塩、ならびにこれを用いた化粧料、医薬組成物、食品組成物、および化粧料キット |
CN105492512A (zh) * | 2013-08-29 | 2016-04-13 | 大日精化工业株式会社 | 水不溶性成形体的制造方法及水不溶性成形体 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2835632B2 (ja) | 1990-01-19 | 1998-12-14 | コニカ株式会社 | ハロゲン化銀カラーネガ写真感光材料 |
JP3215852B2 (ja) | 1997-04-30 | 2001-10-09 | カネボウ株式会社 | 皺改善シート、その使用方法および皺改善シート用水賦活性貼付剤 |
FR2861734B1 (fr) | 2003-04-10 | 2006-04-14 | Corneal Ind | Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus |
CN101500535A (zh) * | 2006-06-28 | 2009-08-05 | 诺维信生物聚合物公司 | 用于化妆品和医学用途的具有几种透明质酸级分的组合物 |
JP2008179629A (ja) | 2006-12-27 | 2008-08-07 | Snt Co | 化粧用シート |
WO2009036120A1 (en) | 2007-09-11 | 2009-03-19 | Cornell Research Foundation, Inc. | Cellular antioxidant activity (caa) assay |
KR101449687B1 (ko) | 2008-03-13 | 2014-10-14 | 주식회사 바이오랜드 | 저분자 및 고분자 히알루론산과 유근피로부터 분리된다당체 추출물을 함유하는 노화방지용 조성물 |
JP5472673B2 (ja) * | 2008-09-29 | 2014-04-16 | コスメディ製薬株式会社 | マイクロニードルアレイ |
JP5840107B2 (ja) * | 2012-06-17 | 2016-01-06 | コスメディ製薬株式会社 | ヒアルロン酸ゲル及びその製造方法 |
EP3017808B1 (en) * | 2013-07-03 | 2022-07-13 | Ritapharma, Co., Ltd. | Water-soluble hyaluronic acid gel and method for producing same |
WO2016136886A1 (ja) * | 2015-02-27 | 2016-09-01 | 大日精化工業株式会社 | 医療用・美容材料及び癒着防止材 |
JP6474360B2 (ja) | 2015-02-27 | 2019-02-27 | 大日精化工業株式会社 | 医療用材料の製造方法、医療用材料、及び癒着防止材 |
WO2016136885A1 (ja) | 2015-02-27 | 2016-09-01 | 大日精化工業株式会社 | 医療用材料の製造方法、医療用材料、及び癒着防止材 |
JP2016166133A (ja) * | 2015-03-09 | 2016-09-15 | キユーピー株式会社 | パック化粧料 |
JP6369992B2 (ja) * | 2015-03-19 | 2018-08-08 | ライオン株式会社 | 溶解型マイクロニードル製剤 |
-
2017
- 2017-09-04 JP JP2017169099A patent/JP6912327B2/ja active Active
-
2018
- 2018-08-16 SG SG11202001216WA patent/SG11202001216WA/en unknown
- 2018-08-16 CA CA3074674A patent/CA3074674C/en active Active
- 2018-08-16 AU AU2018326846A patent/AU2018326846B2/en active Active
- 2018-08-16 EP EP18851040.8A patent/EP3680255A4/en active Pending
- 2018-08-16 WO PCT/JP2018/030400 patent/WO2019044519A1/ja unknown
- 2018-08-16 CN CN201880055978.4A patent/CN111051351A/zh active Pending
- 2018-08-16 US US16/636,547 patent/US11491097B2/en active Active
- 2018-08-16 KR KR1020207007072A patent/KR102322976B1/ko active IP Right Grant
- 2018-08-28 TW TW107129995A patent/TWI820037B/zh active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007297460A (ja) * | 2006-04-28 | 2007-11-15 | Q P Corp | 新規なヒアルロン酸および/またはその塩、ならびにこれを用いた化粧料、医薬組成物、食品組成物、および化粧料キット |
CN105492512A (zh) * | 2013-08-29 | 2016-04-13 | 大日精化工业株式会社 | 水不溶性成形体的制造方法及水不溶性成形体 |
Also Published As
Publication number | Publication date |
---|---|
KR20200041343A (ko) | 2020-04-21 |
KR102322976B1 (ko) | 2021-11-08 |
CN111051351A (zh) | 2020-04-21 |
US11491097B2 (en) | 2022-11-08 |
EP3680255A4 (en) | 2021-06-09 |
TW201919575A (zh) | 2019-06-01 |
SG11202001216WA (en) | 2020-03-30 |
JP6912327B2 (ja) | 2021-08-04 |
AU2018326846A1 (en) | 2020-02-27 |
AU2018326846B2 (en) | 2021-07-22 |
CA3074674A1 (en) | 2019-03-07 |
CA3074674C (en) | 2022-01-04 |
JP2019044086A (ja) | 2019-03-22 |
US20210154126A1 (en) | 2021-05-27 |
WO2019044519A1 (ja) | 2019-03-07 |
EP3680255A1 (en) | 2020-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gierszewska et al. | pH-responsive chitosan/alginate polyelectrolyte complex membranes reinforced by tripolyphosphate | |
Ghorpade et al. | Citric acid crosslinked carboxymethylcellulose-polyvinyl alcohol hydrogel films for extended release of water soluble basic drugs | |
Mali et al. | Synthesis and characterization of hydrogel films of carboxymethyl tamarind gum using citric acid | |
Chang et al. | Superabsorbent hydrogels based on cellulose for smart swelling and controllable delivery | |
Tan et al. | Collagen cryogel cross-linked by naturally derived dialdehyde carboxymethyl cellulose | |
Conzatti et al. | Alginate/chitosan polyelectrolyte complexes: A comparative study of the influence of the drying step on physicochemical properties | |
Martins et al. | Durable pectin/chitosan membranes with self-assembling, water resistance and enhanced mechanical properties | |
Joy et al. | Gelatin—Oxidized carboxymethyl cellulose blend based tubular electrospun scaffold for vascular tissue engineering | |
Jejurikar et al. | Degradable alginate hydrogels crosslinked by the macromolecular crosslinker alginate dialdehyde | |
Gabriele et al. | Ionic and covalent crosslinking in chitosan-succinic acid membranes: Effect on physicochemical properties | |
Santana et al. | Physical evaluation of biodegradable films of calcium alginate plasticized with polyols | |
Trevisol et al. | Alginate and carboxymethyl cellulose in monolayer and bilayer films as wound dressings: Effect of the polymer ratio | |
TWI820037B (zh) | 醫療用材料、美容材料之製造方法及醫療用材料、美容材料 | |
Horn et al. | Influence of collagen addition on the thermal and morphological properties of chitosan/xanthan hydrogels | |
Onyianta et al. | The effects of morpholine pre-treated and carboxymethylated cellulose nanofibrils on the properties of alginate-based hydrogels | |
Singh et al. | Influence of graphene-oxide nanosheets impregnation on properties of sterculia gum-polyacrylamide hydrogel formed by radiation induced polymerization | |
Ahn et al. | Physical state of cellulose in BmimCl: dependence of molar mass on viscoelasticity and sol-gel transition | |
Azevedo et al. | Rheological, water uptake and controlled release properties of a novel self-gelling aldehyde functionalized chitosan | |
He et al. | Preparation of the water-soluble chitosan-coated oxidized regenerated cellulose gauze | |
Vaz et al. | Covalent grafting of chitosan on plasma-treated polytetrafluoroethylene surfaces for biomedical applications | |
Mansouri et al. | Chemical and biological behaviours of hydrogels based on oxidized carboxymethylcellulose coupled to chitosan | |
Zhou et al. | Effects of CaCl2, HCl, acetic acid or citric acid on dynamic mechanical performances and physicochemical properties of sodium alginate edible films | |
JP2009050714A (ja) | 酸化多糖類材料を被覆又は含浸させた材料および生体適合材料 | |
Ren et al. | A preliminary study on fabrication of nanoscale fibrous chitosan membranes in situ by biospecific degradation | |
Deng et al. | Insoluble starch composite foams produced through microwave expansion |